The European Commission has granted marketing authorization for Trodelvy® (sacituzumabgovitecan) as an initial treatment for adults with unresectable or metastatic triple-negative breast cancer (mTNBC) who are ineligible...
GSK plc and Nuvalent, Inc. announced that they have entered into a definitive agreement under which GSK will acquire Nuvalent, a clinical-stage biopharmaceutical company focused on...